AMPHENOL CORP /DE/ financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data AMPHENOL CORP /DE/ files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	6,286	7,011	8,202	8,225	8,599	10,876	12,623	12,555	15,223	23,095
Cost of revenue	4,246	4,701	5,547	5,609	5,935	7,475	8,595	8,471	10,083	14,577
Gross profit	2,040	2,310	2,655	2,616	2,664	3,402	4,028	4,084	5,140	8,518
Research and development	166	194	221	234	261	318	324	342	453	647
Selling, general and administrative	798	878	960	971	1,014	1,226	1,421	1,490	1,855	2,546
Operating income	1,205	1,428	1,687	1,619	1,638	2,105	2,586	2,560	3,157	5,869
Interest expense	72.6	92.3	102	118	115	116	128	140	217	368
Interest income	11.5	20.2
Other non-operating income	8.5	17.1	3.2	8.6	3.6	-0.4	10	29.3	72	99.9
Pre-tax income	1,141	1,352	1,588	1,496	1,527	1,989	2,467	2,455	3,012	5,601
Income tax	309	692	372	332	313	409	551	509	570	1,295
Income from continuing operations				1,155	1,203	1,569	1,902	1,928
Net income to minority interests	9.7	10.2	11.9	9	9.9		14.5	17.5	17.6	35
Net income	823	651	1,205	1,155	1,203	1,591	1,902	1,928	2,424	4,270
EBITDA	1,422	1,654	1,987	1,931	1,947	2,501	2,979	2,966	3,729	6,791
EPS, basic	0.67	0.53	1.00	0.97	1.01	1.33	1.60	1.62	2.01	3.51
EPS, diluted	0.65	0.52	0.97	0.94	0.98	1.27	1.53	1.55	1.92	3.34
Shares, basic (weighted)	1,230	1,220	1,202	1,190	1,192	1,196	1,192	1,193	1,204	1,218
Shares, diluted (weighted)	1,257	1,263	1,247	1,232	1,230	1,251	1,242	1,241	1,264	1,278
Dividend per share	0.15	0.18	0.22	0.24	0.26	0.32	0.41	0.43	0.55	0.75

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	1,035	1,719	1,279	891	1,702	1,197	1,373	1,475	3,317	11,131
Short-term investments	139	34.6	12.4	17.4	36.1	44.3	61.1	185	18.4	304
Receivables	1,349	1,599	1,792	1,736	1,952	2,455	2,631	2,618	3,288	4,717
Inventory	929	1,107	1,234	1,310	1,462	1,894	2,094	2,167	2,546	3,425
Other current assets	140	197	254	256	339	368	320	390	517	691
Total current assets	3,591	4,656	4,572	4,211	5,491	5,958	6,479	6,835	9,686	20,267
Property, plant and equipment	711	817	876	999	1,055	1,175	1,204	1,315	1,712	2,306
Lease right-of-use assets				197	224	245	290	302	384	559
Goodwill	3,679	4,043	4,103	4,867	5,032	6,377	6,446	7,092	8,236	10,575
Intangible assets	474	442	398	442	398	757	734	835	1,225	2,241
Other non-current assets			96.4	296	352	411	463	449	581	847
Total assets	8,499	10,004	10,045	10,816	12,327	14,678	15,326	16,526	21,440	36,237
Accounts payable	678	876	891	867	1,121	1,312	1,309	1,351	1,819	2,662
Accrued liabilities	132	152	157	172	291	366	417	413	530	768
Short-term debt	375	1.1	764	403	230	4	2.7	354	402	937
Total current liabilities	1,635	1,579	2,451	2,133	2,304	2,447	2,676	3,153	4,084	6,803
Long-term debt	2,636	3,542	2,806	3,203	3,636	4,796	4,575	3,984	6,484	14,565
Lease liabilities				145	161	180	209	212	286	425
Other non-current liabilities	139	326	277	424	407	439	443	454	509	789
Total liabilities	4,776	5,961	5,981	6,219	6,875	8,299	8,232	8,100	11,584	22,727
Total debt	3,011	3,543	3,571	3,607	3,867	4,800	4,578	4,337	6,886	15,502
Paid-in capital	1,021	1,249	1,433	1,683	2,068	2,409	2,650	3,101	3,602	4,232
Retained earnings	3,123	2,942	3,029	3,348	3,705	4,279	4,979	5,921	7,105	9,854
Treasury stock			-55	-70.8	-111	-100	-79.8	-143	-200	-196
Other comprehensive income	-469	-201	-390	-431	-278	-287	-535	-534	-716	-480
Shareholders' equity	3,675	3,990	4,017	4,530	5,385	6,302	7,016	8,347	9,792	13,413
Minority interests	48.2	53.6	47.2	65.9	67	58.1	57.9	49.3	55.4	87.3
Total equity	3,723	4,043	4,064	4,596	5,452	6,360	7,074	8,396	9,847	13,500
Total liabilities and equity	8,499	10,004	10,045	10,816	12,327	14,678	15,326	16,526	21,440	36,237
Shares outstanding	1,230	1,220	1,191	596	1,197	1,198	595	1,198	1,209	1,227

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	833	661	1,217	1,164	1,213	1,602	1,917	1,946	2,442	4,305
Depreciation and amortization	217	227	300	312	308	396	393	406	573	922
Stock-based compensation	47.6	49.7	55.6	63	70.5	83	89.5	99	110	135
Deferred income tax	-29.9	186	-12	15.2	30.8	-29.6	-4.7	-58.8	-82.8	-65.6
Change in receivables	-166	-147	-238	117	-146	-398	-273	146	-587	-964
Change in inventory	-14.2	-100	-173	-3.4	-102	-263	-279	71.4	-200	-487
Change in payables	47.8	141	48.8	-60.2	204	132	62.5	-34.6	423	554
Cash from operations	1,078	1,144	1,113	1,502	1,592	1,540	2,175	2,529	2,815	5,375
Capital expenditures	-191	-227	-311	-295	-277	-360	-384	-373	-665	-997
Acquisitions	-1,305	-266	-159	-937	-50.4	-2,225	-288	-970	-2,156	-3,819
Purchases of investments	-232	-40.2	-44.5	-65.4	-142	-165	-309	-306	-26.2	-309
Sales and maturities of investments					123	156	228	246	190	27.6
Cash from investing	-1,613	-380	-442	-1,229	-334	-1,888	-731	-1,394	-2,649	-5,082
Debt issued		749	572	1,399	942	752	5.8	355	2,991	8,922
Debt repaid		-375
Stock issued	147	184	131	246	386	289	185	395	447	553
Share buybacks	-326	-618	-935	-602	-641	-662	-731	-585	-689	-665
Dividends paid	-173	-205	-254	-280	-298	-347	-477	-501	-595	-802
Cash from financing	-134	-140	-1,070	-648	-517	-145	-1,197	-1,012	1,730	7,423
Exchange rate effect	-34	60.6
Net change in cash	-703	685	-440	-388	811	-505	176	102	1,842	7,814
Free cash flow	887	918	802	1,207	1,315	1,180	1,791	2,156	2,149	4,378
Interest paid	68.5	84.3	94.2	117	105	112	124	129	180	288
Income taxes paid	247	325	393	408	337	446	478	560	650	1,084

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $79.95 on November 10, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	38.8%	Gross profit / revenue.
Operating margin	27.7%	Operating income / revenue.
EBITDA margin	32.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	25.8%	Pre-tax income / revenue.
Net margin	18.0%	Net income / revenue.
FCF margin	15.5%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	19.6%	Cash from operations / revenue.
Effective tax rate	29.7%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	34.6%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	12.6%	Net income / average total assets.
Return on invested capital (ROIC)	20.9%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
SG&A / revenue	10.5%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.5%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	4.1%	Capital expenditures / revenue.
D&A / revenue	4.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	51.7%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	22.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	21.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	65.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	28.4%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	26.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	85.9%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	31.4%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	29.1%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	82.1%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	31.6%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	28.4%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	76.2%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	30.9%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	28.8%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	74.0%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	29.7%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	27.8%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	91.0%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	35.2%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	27.6%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	103.7%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	34.7%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	27.2%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y	35.5%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	22.5%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y	23.4%	Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	37.0%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	24.1%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	20.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	69.0%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	33.2%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	24.1%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.1%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.94x	Current assets / current liabilities.
Quick ratio	1.30x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.53x	(Cash + short-term investments) / current liabilities.
Debt / equity	1.04x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	38.0%	Total debt / total assets.
Liabilities / assets	63.3%	Total liabilities / total assets.
Net debt	$12.57B	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	1.19x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	12.0x	Operating income / interest expense.
Working capital	$9.44B	Current assets - current liabilities.
Goodwill and intangibles / assets	49.0%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$5.92B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.70x	Revenue / average total assets.
Fixed asset turnover	10.2x	Revenue / average property, plant and equipment.
Inventory turnover	3.84x	Cost of revenue / average inventory.
Days inventory	95 days	365 x average inventory / cost of revenue.
Receivables turnover	4.25x	Revenue / average receivables.
Days sales outstanding	86 days	365 x average receivables / revenue.
Days payables	88 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	93 days	Days inventory + days sales outstanding - days payables.
FCF conversion	86.3%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	21.0%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$2.30	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$12.79	Revenue / diluted weighted shares.
FCF per share	$1.98	Free cash flow / diluted weighted shares.
Operating cash flow per share	$2.51	Cash from operations / diluted weighted shares.
Book value per share	$6.63	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$2.29	Tangible book value / shares outstanding.
Cash per share	$2.05	(Cash + short-term investments) / shares outstanding.
Payout ratio	18.9%	Dividends paid / net income, when net income is positive.
Dividends / FCF	21.9%	Dividends paid / free cash flow, when free cash flow is positive.
Buybacks / FCF	15.7%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$98.58B	Share price x shares outstanding.
Enterprise value	$111.15B	Market cap + total debt - cash - short-term investments.
P/E	16.6x	Market cap / net income. Only when net income is positive.
P/S	2.98x	Market cap / revenue.
P/B	5.76x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	19.2x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	15.2x	Market cap / cash from operations, when positive.
EV/Sales	3.36x	Enterprise value / revenue.
EV/EBIT	12.1x	Enterprise value / operating income, when both are positive.
EV/EBITDA	10.5x	Enterprise value / EBITDA, when both are positive.
EV/FCF	21.7x	Enterprise value / free cash flow, when both are positive.
FCF yield	5.2%	Free cash flow / market cap.
Earnings yield	6.0%	Net income / market cap (the inverse of P/E).
Dividend yield	1.1%	Dividends paid over the period / market cap.
Shareholder yield	2.0%	(Dividends paid + share buybacks) / market cap.
PEG	0.56x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was AMPHENOL CORP /DE/'s revenue in fiscal 2025?

AMPHENOL CORP /DE/ reported revenue of $23.09B for fiscal 2025, 51.7% higher than the year before.

Was AMPHENOL CORP /DE/ profitable in fiscal 2025?

Yes. Net income was $4.27B, a net margin of 18.5%.

How much free cash flow did AMPHENOL CORP /DE/ generate in fiscal 2025?

Cash from operations of $5.37B minus capital expenditures of $996.6M left free cash flow of $4.38B.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to AMPHENOL CORP /DE/